Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 13/20 | 0.49 |
| ▸ | RAB9A | P51151 | 12/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 7/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 7/20 | 0.49 |
| ▸ | RELA | Q04206 | 7/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6316253 | 0.83 | RAB9A (0.51) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL6318150 | 0.82 | CA1 (0.49) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6316860 | 0.78 | RAB9A (0.57) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL6316836 | 0.78 | SMN1; SMN2 (0.51) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL6316411 | 0.77 | RAB9A (0.50) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL6316714 | 0.76 | RAB9A (0.45) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL6321873 | 0.75 | RAB9A (0.53) | NPC1RAB9ASMN1; SMN2LMNAKMT2A | |
| SCHEMBL6322557 | 0.75 | NPC1 (0.45) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL6315080 | 0.75 | MAPT (0.47) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL6315247 | 0.74 | RAB9A (0.47) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | claimed |
| EP-1435948-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | claimed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | claimed |
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | disclosed |
| EP-1435948-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | MAP3K9, MAP3K19, MAP4K2 | NPC1 3741/4885RAB9A 1754/4885SMN1; SMN2 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.